Identification of Intracellular Residues in the Dopamine Transporter Critical for Regulation of Transporter Conformation and Cocaine Binding*

Recently we showed evidence that mutation of Tyr-335 to Ala (Y335A) in the human dopamine transporter (hDAT) alters the conformational equilibrium of the transport cycle. Here, by substituting, one at a time, 16 different bulky or charged intracellular residues, we identify three residues, Lys-264, Asp-345, and Asp-436, the mutation of which to alanine produces a phenotype similar to that of Y335A. Like Y335A, the mutants (K264A, D345A, and D436A) were characterized by low uptake capacity that was potentiated by Zn2+. Moreover, the mutants displayed lower affinity for cocaine and other inhibitors, suggesting a role for these residues in maintaining the structural integrity of the inhibitor binding crevice. The conformational state of K264A, Y335A, and D345A was investigated by assessing the accessibility to MTSET ([2-(trimethylammonium)ethyl]-methanethiosulfonate) of a cysteine engineered into position 159 (I159C) in transmembrane segment 3 of the MTSET-insensitive “E2C” background (C90A/C306A). Unlike its effect at the corresponding position in the homologous norepinephrine transporter (NET I155C), MTSET did not inhibit uptake mediated by E2C I159C. Furthermore, no inhibition was observed upon treatment with MTSET in the presence of dopamine, cocaine, or Zn2+. Without Zn2+, E2C I159C/K264A, E2C I159C/Y335A, and E2C I159C/D345A were also not inactivated by MTSET. In the presence of Zn2+ (10 μm), however, MTSET (0.5 mm) caused up to ∼60% inactivation. As in NET I155C, this inactivation was protected by dopamine and enhanced by cocaine. These data are consistent with a Zn2+-dependent partial reversal of a constitutively altered conformational equilibrium in the mutant transporters. They also suggest that the conformational equilibrium produced by the mutations resembles that of the NET more than that of the DAT. Moreover, the data provide evidence that the cocaine-bound state of both DAT mutants and of the NET is structurally distinct from the cocaine-bound state of the DAT.

[1]  G. Rudnick,et al.  Permeation and gating residues in serotonin transporter. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Javitch,et al.  Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Javitch,et al.  Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Uhl,et al.  Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. , 2002, Molecular pharmacology.

[5]  Jonathan A. Javitch,et al.  The Uptake Inhibitors Cocaine and Benztropine Differentially Alter the Conformation of the Human Dopamine Transporter* , 2001, The Journal of Biological Chemistry.

[6]  S. Amara,et al.  Neurotransmitter transporters: recent progress. , 1993, Annual review of neuroscience.

[7]  L. Bryan-Lluka Neurotransmitter Transporters: Structure, Function and Regulation , 2003 .

[8]  U. Gether,et al.  Defining Proximity Relationships in the Tertiary Structure of the Dopamine Transporter , 1999, The Journal of Biological Chemistry.

[9]  M. Caron,et al.  Oligomerization and Trafficking of the Human Dopamine Transporter , 2003, The Journal of Biological Chemistry.

[10]  T. Litman,et al.  Generation of an activating Zn2+ switch in the dopamine transporter: Mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Reith,et al.  The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site‐directed mutagenesis , 2001, Journal of neurochemistry.

[12]  M. Reith,et al.  Dual incorporation of photoaffinity ligands on dopamine transporters implicates proximity of labeled domains. , 2001, Molecular pharmacology.

[13]  M. Reith,et al.  Structure and function of the dopamine transporter. , 2000, European journal of pharmacology.

[14]  H. Weinstein,et al.  A Structural Context for Studying Neurotransmitter Transporter Function , 2004 .

[15]  George R. Uhl,et al.  Dopamine Transporter Transmembrane Domain Polar Mutants: ΔG and ΔΔG Values Implicate Regions Important for Transporter Functions , 2000 .

[16]  G. Rudnick,et al.  A Conformationally Sensitive Residue on the Cytoplasmic Surface of Serotonin Transporter* , 2001, The Journal of Biological Chemistry.

[17]  J. Javitch,et al.  N-terminal Truncation of the Dopamine Transporter Abolishes Phorbol Ester- and Substance P Receptor-stimulated Phosphorylation without Impairing Transporter Internalization* , 2003, The Journal of Biological Chemistry.

[18]  G. Rudnick,et al.  Accessibility and Conformational Coupling in Serotonin Transporter Predicted Internal Domains , 2002, The Journal of Neuroscience.

[19]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[20]  Marc G Caron,et al.  Monoamine transporters: from genes to behavior. , 2003, Annual review of pharmacology and toxicology.

[21]  K. Fahmy,et al.  A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin. , 1994, The Journal of biological chemistry.

[22]  G R Uhl,et al.  Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  J. Javitch,et al.  Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Sitte,et al.  Oligomerization of the Human Serotonin Transporter and of the Rat GABA Transporter 1 Visualized by Fluorescence Resonance Energy Transfer Microscopy in Living Cells* , 2001, The Journal of Biological Chemistry.

[25]  J. Javitch,et al.  Zn2+ site engineering at the oligomeric interface of the dopamine transporter , 2002, FEBS letters.

[26]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[27]  H. Feirabend,et al.  Preservation and staining of myelinated nerve fibers. , 1998, Methods.

[28]  R. Blakely,et al.  Biogenic amine transporters: regulation in flux , 2000, Current Opinion in Neurobiology.

[29]  U. Gether,et al.  The monoamine neurotransmitter transporters: structure, conformational changes and molecular gating. , 2001, Current opinion in drug discovery & development.

[30]  H Weinstein,et al.  Structural probing of a microdomain in the dopamine transporter by engineering of artificial Zn2+ binding sites. , 2000, Biochemistry.

[31]  J. B. Justice,et al.  Novel tropane-based irreversible ligands for the dopamine transporter. , 2001, Journal of medicinal chemistry.

[32]  H. Gu,et al.  Cocaine affinity decreased by mutations of aromatic residue phenylalanine 105 in the transmembrane domain 2 of dopamine transporter. , 2003, Molecular pharmacology.

[33]  J. B. Justice,et al.  Transport-dependent Accessibility of a Cytoplasmic Loop Cysteine in the Human Dopamine Transporter* , 2000, The Journal of Biological Chemistry.

[34]  J. Ballesteros,et al.  Activation of the β2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6* , 2001, The Journal of Biological Chemistry.

[35]  M. Saraste,et al.  FEBS Lett , 2000 .

[36]  E. Nielsen,et al.  Delineation of an endogenous zinc‐binding site in the human dopamine transporter , 1998, The EMBO journal.

[37]  R. Lefkowitz,et al.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.

[38]  M. Caron,et al.  Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. , 1992, Molecular pharmacology.

[39]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[40]  T. Schwartz,et al.  Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors , 1990, FEBS letters.

[41]  U. Gether,et al.  Residues in the Extracellular Loop 4 Are Critical for Maintaining the Conformational Equilibrium of the γ-Aminobutyric Acid Transporter-1* , 2003, Journal of Biological Chemistry.

[42]  T. Schwartz,et al.  Stable expression of high affinity NK1 (substance P) and NK2(neurokinin A) receptors but low affinity NK3 (neurokinin B) receptors in transfected CHO cells , 1992, FEBS letters.